Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.
作者信息
Jani Prachi, Vissing Megan B, Ahmed Salman, Sluzevich Jason C, Aulakh Sonikpreet, Alegria Victoria, Ailawadhi Meghna, Chanan-Khan Asher, Ailawadhi Sikander
机构信息
Mayo Clinic, Jacksonville, FL.
出版信息
J Oncol Pract. 2018 Jun;14(6):387-388. doi: 10.1200/JOP.18.00050. Epub 2018 Mar 20.
Abstract
摘要
相似文献
1
Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.依鲁替尼用于施尼茨勒综合征的治疗：一种针对罕见病症的新型疗法。
J Oncol Pract. 2018 Jun;14(6):387-388. doi: 10.1200/JOP.18.00050. Epub 2018 Mar 20.
2
Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.伊布替尼是治疗B细胞原淋巴细胞白血病的一种有效疗法。
Br J Haematol. 2017 Nov;179(3):501-503. doi: 10.1111/bjh.14224. Epub 2016 Jul 8.
3
Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.伊布替尼对难治性Ⅱ型冷球蛋白血症有效。
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):e629-e632. doi: 10.1016/j.clml.2019.07.442. Epub 2019 Sep 3.
4
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？依鲁替尼应作为标准一线治疗。
Clin Adv Hematol Oncol. 2016 May;14(5):330-3.
5
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.依鲁替尼作为挽救治疗用于一名经治的不适合进行化疗的套细胞淋巴瘤合并中枢神经系统受累患者。
Leuk Lymphoma. 2018 Jul;59(7):1734-1737. doi: 10.1080/10428194.2017.1387910. Epub 2017 Oct 11.
6
How I treat CLL patients with ibrutinib.我如何用伊布替尼治疗 CLL 患者。
Blood. 2018 Jan 25;131(4):379-386. doi: 10.1182/blood-2017-08-764712. Epub 2017 Dec 18.
7
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.依鲁替尼用于日本复发/难治性套细胞淋巴瘤患者的II期研究的最终分析。
J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.
8
Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.针对交叉情况进行生存调整：伊布替尼与苯丁酸氮芥治疗未经治疗的老年慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的3期研究
Haematologica. 2018 Jun;103(6):e249-e251. doi: 10.3324/haematol.2017.175380. Epub 2017 Nov 23.
9
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.伊布替尼单药治疗复发/难治性双表达 B 细胞淋巴瘤患者的结局。
Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401.
10
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.伊布替尼治疗复发/难治性慢性淋巴细胞白血病的老年患者：法国71例患者的真实世界经验：法国创新白血病组织（FILO）组的一项研究
Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29.
引用本文的文献
1
Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome.病例报告：硼替佐米对施尼茨勒综合征患者的治疗应用
Front Immunol. 2025 Jan 28;16:1520470. doi: 10.3389/fimmu.2025.1520470. eCollection 2025.
2
Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome.一种独特且神秘的自身炎症性疾病——施尼茨勒综合征的背景与临床特征
Int J Mol Sci. 2025 Jan 12;26(2):598. doi: 10.3390/ijms26020598.
3
Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management.施尼茨勒综合征：发病机制、临床表现及当前治疗方法的研究进展。
Biomolecules. 2024 May 31;14(6):646. doi: 10.3390/biom14060646.
4
Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.病例报告：伊布替尼在 Schnitzler 综合征患者中的治疗应用。
Front Immunol. 2022 Apr 20;13:894464. doi: 10.3389/fimmu.2022.894464. eCollection 2022.
本文引用的文献
1
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.布鲁顿酪氨酸激酶抑制剂依鲁替尼在普通社区各类B细胞恶性肿瘤中的疗效和耐受性分析：一项单中心经验
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S53-S61. doi: 10.1016/j.clml.2017.02.011.
2
Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.在华氏巨球蛋白血症中靶向MYD88的新方法。
Expert Rev Hematol. 2017 Aug;10(8):739-744. doi: 10.1080/17474086.2017.1343661. Epub 2017 Jun 28.
3
Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.人 NACHT、LRR 和 PYD 结构域包含蛋白 3（NLRP3）炎症小体的活性受布鲁顿酪氨酸激酶调节，并且可能成为其作用靶点。
J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10. doi: 10.1016/j.jaci.2017.01.017. Epub 2017 Feb 16.
4
Are you sure this is Waldenstrom macroglobulinemia?你确定这是瓦尔登斯特伦巨球蛋白血症吗？
Hematology Am Soc Hematol Educ Program. 2012;2012:586-94. doi: 10.1182/asheducation-2012.1.586.
5
The Schnitzler syndrome. Schnitzler 综合征。
Orphanet J Rare Dis. 2010 Dec 8;5:38. doi: 10.1186/1750-1172-5-38.
Zotero 插件